A new trading day began on May 23, 2023, with Viridian Therapeutics Inc. (NASDAQ: VRDN) stock priced at $24.67, up 0.48% from the previous day of trading. During the day, the shares moved up to $25.17 and dropped to $24.45 before settling in for the closing price of $24.76. VRDN’s price has ranged from $9.84 to $39.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -15.00%. Meanwhile, its annual earnings per share averaged 39.30%. With a float of $39.68 million, this company’s outstanding shares have now reached $42.24 million.
Considering the fact that the conglomerate employs 86 people, you should pay attention to its efficiency factor.
Viridian Therapeutics Inc. (VRDN) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Viridian Therapeutics Inc. is 1.91%, while institutional ownership is 95.00%. The most recent insider transaction that took place on Apr 12, was worth 101,479. In this transaction Chief Executive Officer of this company bought 4,000 shares at a rate of $25.37, taking the stock ownership to the 259,500 shares. Before that another transaction happened on Mar 13, when Company’s Chief Executive Officer bought 5,500 for $29.15, making the entire transaction worth $160,324. This insider now owns 255,500 shares in total.
Viridian Therapeutics Inc. (VRDN) Earnings and Forecasts
In its latest quarterly report, released on 3/30/2023, the company reported earnings of -$1.61 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). This company achieved a net margin of -7329.23 while generating a return on equity of -44.57. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 39.30% per share during the next fiscal year.
Viridian Therapeutics Inc. (NASDAQ: VRDN) Trading Performance Indicators
Here are Viridian Therapeutics Inc.’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 12.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 617.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.66, a number that is poised to hit -1.27 in the next quarter and is forecasted to reach -4.77 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc. (VRDN)
Compared to the last year’s volume of 0.6 million, its volume of 0.69 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 58.25%. Additionally, its Average True Range was 1.28.
During the past 100 days, Viridian Therapeutics Inc.’s (VRDN) raw stochastic average was set at 17.14%, which indicates a significant decrease from 46.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.34% in the past 14 days, which was lower than the 52.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $26.19, while its 200-day Moving Average is $26.02. Nevertheless, the first resistance level for the watch stands at $25.22 in the near term. At $25.55, the stock is likely to face the second major resistance level. The third major resistance level sits at $25.94. If the price goes on to break the first support level at $24.50, it is likely to go to the next support level at $24.11. Should the price break the second support level, the third support level stands at $23.78.
Viridian Therapeutics Inc. (NASDAQ: VRDN) Key Stats
With a market capitalization of 1.05 billion, the company has a total of 43,132K Shares Outstanding. Currently, annual sales are 1,770 K while annual income is -129,870 K. The company’s previous quarter sales were 100 K while its latest quarter income was -68,150 K.
